Cytokine Signalling Forum
Cours de FMC
Focus on Tofacitinib
Developed by CESAS Medical, under the auspices of the University of Glasgow. This activity is supported by unrestricted educational grants from Pfizer Italia S.R.L., Lilly and R-Pharm.Release date: 14 July 2017
Estimated time to complete activity: 1 hour 15 minutes
Compatible with all modern browsers and mobile devices
TARGET AUDIENCE
This activity is designed for rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with rheumatic disease.
PROGRAM OVERVIEW
Following the approval of tofacitinib in the European Union as well as by the FDA, this course provides an in-depth examination of emerging data with respect to the mechanism of action of tofacitinib, and efficacy data from the ORAL clinical trial programme in rheumatoid arthritis. An update regarding the safety of tofacitinib is provided, with clinical trials and real-life data presented. Current perceptions of tofacitinib are also discussed.
EDUCATIONAL OBJECTIVES
By following this programme, the learner will be able to:
- Understand the JAK/STAT pathway and its implications on rheumatic disease
- Understand the mechanism of action of JAK inhibitors
- Evaluate the efficacy of tofacitinib across a number of patient groups
- Understand the safety profile of tofacitinib in clinical practice
INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.
| Module | Présentateur | Vidéo | Questions |
|---|---|---|---|
| Introduction |
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS), Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the leading trans-national society for rheumatology across Europe. Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA. He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine. |
01:39 | |
| JAK-Kinase Targeting in RA: Mechanism of Action |
Professor Iain B. McInnes
Vice Principal and Head of College of Medical, Veterinary and Life Sciences (MVLS), Professor Iain McInnes is the Vice Principal and Head of College of MVLS in the University of Glasgow, UK. He is also the leading trans-national society for rheumatology across Europe. Professor McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA. He has extensive experience in leading multicentre programmes, nationally and internationally. Professor McInnes is also Director of the Scottish MRC Clinical Pharmacology and Pathology Clinical PhD Training Programme; Chief Investigator for the Scottish Early RA Cohort (SERA) and the related SMS-IC biomarker discovery programme (PROMISERA); and Chief Investigator of numerous global phase II and III clinical trials of novel immune therapies His major interest is in the biology of inflammatory synovitis in rheumatoid arthritis, psoriatic arthritis and septic arthritis. He operates on a translational science programme in which state of the art cellular and molecular biology techniques are applied to elucidate the mechanisms underlying the perpetuation of a range of chronic diseases seeking to build precision medicine approaches and new therapeutics thereafter. He received the Sir James Black Prize Medal, a prestigious award in medicine in 2016 by the Royal Society of Edinburgh for his outstanding contribution to the field of immunology. In 2019, Professor McInnes was awarded a CBE for his services to Medicine. |
30:28 | 4 |
| Tofacitinib: Efficacy in Focus |
Professor Peter Nash
Associate Professor, School of Medicine, Peter Nash is Professor at the School of Medicine, Griffith University, Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia. He serves on the Scientific Advisory committee and ASMPOC of the Australian Rheumatology Association, having Chaired the Therapeutics and the Professional Affairs committees of the ARA and served on the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. In addition, he is a member of the International Steering Committee of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Professor Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies. He has published over 180 peer-reviewed papers and five book chapters, and serves on the editorial board of Annals of the Rheumatic Diseases and RMD Open and acts as reviewer for many rheumatology journals. His special interests include metabolic bone disease and novel therapeutics. |
17:46 | 5 |
| Tofacitinib: Update on Safety |
Professor Kevin Winthrop
Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases. |
14:41 | 4 |
| Evaluation | 5 |
Date de préparation: 14 July 2017